GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (NAS:CYTO) » Definitions » Cash Ratio

Altamira Therapeutics (Altamira Therapeutics) Cash Ratio : 0.69 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Altamira Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Altamira Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 was 0.69.

Altamira Therapeutics has a Cash Ratio of 0.69. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Altamira Therapeutics's Cash Ratio or its related term are showing as below:

CYTO' s Cash Ratio Range Over the Past 10 Years
Min: 0.2   Med: 1.44   Max: 12.83
Current: 0.69

During the past 13 years, Altamira Therapeutics's highest Cash Ratio was 12.83. The lowest was 0.20. And the median was 1.44.

CYTO's Cash Ratio is ranked worse than
79.3% of 1522 companies
in the Biotechnology industry
Industry Median: 2.93 vs CYTO: 0.69

Altamira Therapeutics Cash Ratio Historical Data

The historical data trend for Altamira Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Cash Ratio Chart

Altamira Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 3.72 0.20 - 0.69

Altamira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.04 - 0.01 0.69

Competitive Comparison of Altamira Therapeutics's Cash Ratio

For the Biotechnology subindustry, Altamira Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altamira Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Cash Ratio falls into.



Altamira Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Altamira Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.713/1.028
=0.69

Altamira Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.713/1.028
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics  (NAS:CYTO) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Altamira Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics (Altamira Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (Altamira Therapeutics) Headlines

From GuruFocus

Altamira Therapeutics Provides Year-End 2022 Business Update

By Value_Insider Value_Insider 12-19-2022

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

By Stock market mentor Stock market mentor 01-24-2023